Vaxcyte, Inc.

Vaxcyte (PCVX) reported zero cyber incidents and zero red-flag 8-Ks over the past 90 days, suggesting operational stability in the recent window. However, low signal in a 90-day snapshot does not mean low risk; a vaccine-stage biotech faces material financing and dilution exposure that requires deeper context. The full $49 Report extends analysis to 12 months of filings, maps dilution risk scores across equity raises, and flags AI-detected anomalies in officer disclosures and 8-K patterns. The full $49 Report adds comprehensive dilution history, financing runway signals, and 12-month red-flag context.